Synopsis
0
VMF
DRUG PRODUCT COMPOSITIONS
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
API SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
USDMF
Veranova: A CDMO that manages complexity with confidence.
GDUFA
DMF Review : Complete
Rev. Date : 2015-02-13
Pay. Date : 2015-02-02
DMF Number : 7145
Submission : 1987-09-17
Status :
Type : II
TAPI, a leading global supplier of APIs, provides over 350 products and customized CDMO solutions for every stage of development.
GDUFA
DMF Review : Complete
Rev. Date : 2012-12-24
Pay. Date : 2012-12-03
DMF Number : 17659
Submission : 2004-09-08
Status :
Type : II
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]CEP/COS
Veranova: A CDMO that manages complexity with confidence.
Certificate Number : R1-CEP 2004-104 - Rev 03
Status : Valid
Issue Date : 2023-03-27
Type : Chemical
Substance Number : 1081
TAPI, a leading global supplier of APIs, provides over 350 products and customized CDMO solutions for every stage of development.
Certificate Number : CEP 2000-375 - Rev 05
Status : Valid
Issue Date : 2025-03-21
Type : Chemical
Substance Number : 1081
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] JDMF
Veranova: A CDMO that manages complexity with confidence.
Registration Number : 222MF10101
Registrant's Address : 25 Patton Road, Devens, MA 01434 USA
Initial Date of Registration : 2010-03-18
Latest Date of Registration : 2010-03-18
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]EU WC
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]KDMF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]NDC API
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Listed Suppliers
LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
About the Company : LGM Pharma is a global leader in sourcing hard-to-find APIs and intermediates for pharmaceutical and biotech industries. LGM also operates as a full-service CDMO, offering formulat...
Veranova: A CDMO that manages complexity with confidence.
About the Company : Veranova is a global leader in developing and manufacturing specialist and complex APIs for pharma and biotech customers, with over 50 years of experience supporting the healthcare...
HRV Pharma - Market Expansion Leader in Pharmaceuticals.
About the Company : HRV Pharma is a global manufacturer, seller, and exporter of APIs, intermediates, pellets, food-grade chemicals, food additives, and food ingredients. The company provides sourcing...
Shanghai Minbiotech is the leading producer of biopharmaceuticals and a variety of high-end generic & innovative drugs.
About the Company : Shanghai Minbiotech is specializing in the R&D and production of advanced pharmaceutical intermediates and biological APIs. There are more than 1000 square meters of R&D centers in...
TAPI, a leading global supplier of APIs, provides over 350 products and customized CDMO solutions for every stage of development.
About the Company : Founded in 1935, TAPI Technology & API Services has a long legacy of advancing health through innovation. Today, we offer one of the industry’s most comprehensive API portfolios ...
Willow Birch Pharma delivers trusted, high-quality APIs nationwide with unmatched service, compliance, and competitive value.
About the Company : Willow Birch Pharma, Inc. is a premier supplier of bulk APIs to North American Compounding Pharmacies, sourcing from FDA registered and GMP manufacturers. With licenses in all 50 s...
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]API Reference Price
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
Drugs in Development
Lead Product(s) : Iniparib,Carboplatin,Doxorubicin Hydrochloride,Gemcitabine,Irinotecan Hydrochloride,Paclitaxel,Topotecan Hydrochloride
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Iniparib is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Neoplasms.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 08, 2012
Lead Product(s) : Ombrabulin,Paclitaxel,Carboplatin
Therapeutic Area : Oncology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Ombrabulin is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Ovarian Neoplasms.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 11, 2011
Lead Product(s) : Ombrabulin,Paclitaxel,Carboplatin
Therapeutic Area : Oncology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Ombrabulin is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neoplasms.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 10, 2011
Lead Product(s) : Iniparib,Gemcitabine,Carboplatin
Therapeutic Area : Oncology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Iniparib is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neoplasms.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 04, 2010
Lead Product(s) : Gemcitabine,Carboplatin,Iniparib
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Gemcitabine is a Cytotoxic Drug drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Lung Neoplasms.
Product Name : Undisclosed
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
March 08, 2010
Lead Product(s) : Iniparib,Gemcitabine,Carboplatin
Therapeutic Area : Oncology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Iniparib is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Breast Neoplasms.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 11, 2010
Lead Product(s) : ABBV-706,Atezolizumab,Etoposide,Carboplatin,Lurbinectedin
Therapeutic Area : Oncology
Highest Development Status : Phase II/ Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : (ABBV-706) is currently being evaluated in Phase II/ Phase III clinical studies for the treatment of Small Cell Lung Carcinoma.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
September 04, 2025
Lead Product(s) : Mirvetuximab Soravtansine,Bevacizumab,Carboplatin
Therapeutic Area : Oncology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
IV Mirvetuximab Soravtansine Safety & Disease Activity In Adult Ovarian Cancer Patients
Details : Mirvetuximab Soravtansine is a Antibody-drug Conjugate drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Ovarian Neoplasms.
Product Name : Undisclosed
Product Type : Antibody-drug Conjugate
Upfront Cash : Inapplicable
July 11, 2025
Lead Product(s) : IMGN151,Carboplatin,Olaparib,Bevacizumab
Therapeutic Area : Oncology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
IMGN151 IV Safety & Disease Activity In Gynecologic Cancers ± Combination
Details : IMGN151 is a Antibody-drug Conjugate drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Genital Neoplasms, Female.
Product Name : Undisclosed
Product Type : Antibody-drug Conjugate
Upfront Cash : Inapplicable
June 17, 2025
Lead Product(s) : Carboplatin,Mirvetuximab Soravtansine
Therapeutic Area : Oncology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Carboplatin is a Cytotoxic Drug drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Carcinoma, Ovarian Epithelial.
Product Name : Undisclosed
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
March 24, 2025
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]INTERMEDIATE SUPPLIERS
Minakem delivers API, HPAPI, steroids & CDMO services for generics with FDA/GMP certification, regulatory know-how & proven success.
1,1-Cyclobutane Dicarboxylic Acid
CAS Number : 5445-51-2
End Use API : Carboplatin
About The Company : MINAKEM is a cGMP custom manufacturer specializing in small molecule APIs, HPAPIs, and steroids. Its highly skilled R&D teams, supported by strong analytical an...
Minakem delivers API, HPAPI, steroids & CDMO services for generics with FDA/GMP certification, regulatory know-how & proven success.
Diethyl-1,1-Cyclobutane Dicarboxylate
CAS Number : 3779-29-1
End Use API : Carboplatin
About The Company : MINAKEM is a cGMP custom manufacturer specializing in small molecule APIs, HPAPIs, and steroids. Its highly skilled R&D teams, supported by strong analytical an...
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDA Orange Book
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Europe
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Canada
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Australia
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]South Africa
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Listed Dossiers
NanoAlvand is the entrance to Global Markets as a trusted Highly Potent Products manufacturer.
Regulatory Info :
Registration Country : Iran
Brand Name : Carbonatin
Dosage Form : Vial
Dosage Strength : 50MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Iran
NanoAlvand is the entrance to Global Markets as a trusted Highly Potent Products manufacturer.
Regulatory Info :
Registration Country : Iran
Brand Name : Carbonatin
Dosage Form : Vial
Dosage Strength : 150MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Iran
Supriya Lifesciences is a cGMP-compliant API manufacturing organization with a leadership position across key & niche products.
Regulatory Info :
Registration Country : India
Brand Name :
Dosage Form : Injection
Dosage Strength : 50ML/5ML
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : India
Supriya Lifesciences is a cGMP-compliant API manufacturing organization with a leadership position across key & niche products.
Regulatory Info :
Registration Country : India
Brand Name :
Dosage Form : Injection
Dosage Strength : 150MG/15ML
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : India
Supriya Lifesciences is a cGMP-compliant API manufacturing organization with a leadership position across key & niche products.
Regulatory Info :
Registration Country : India
Brand Name :
Dosage Form : Injection
Dosage Strength : 450MG/45ML
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : India
Supriya Lifesciences is a cGMP-compliant API manufacturing organization with a leadership position across key & niche products.
Regulatory Info :
Registration Country : India
Brand Name :
Dosage Form : Injection
Dosage Strength : 600MG/60ML
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : India
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Related Excipient Companies
Rochem International Inc
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]SPI Pharma
SPI Pharma has been solving formulation challenges using superior functional materials.
Dosage Form : Tablet
Grade : Oral
SPI Pharma has been solving formulation challenges using superior functional materials.
Dosage Form : Tablet
Grade : Oral
SPI Pharma has been solving formulation challenges using superior functional materials.
Dosage Form : Tablet
Grade : Oral
Application : Disintegrants & Superdisintegrants
Excipient Details : Mannogem 2080 exhibits excellent flow, disintegration and compression properties.
SPI Pharma has been solving formulation challenges using superior functional materials.
Dosage Form : Orodispersible Tablet
Grade : Oral
SPI Pharma has been solving formulation challenges using superior functional materials.
Dosage Form : Orodispersible Tablet
Grade : Oral
SPI Pharma has been solving formulation challenges using superior functional materials.
Dosage Form : Tablet
Grade : Oral
SPI Pharma has been solving formulation challenges using superior functional materials.
Dosage Form : Tablet
Grade : Oral
SPI Pharma has been solving formulation challenges using superior functional materials.
Dosage Form : Tablet
Grade : Oral
SPI Pharma has been solving formulation challenges using superior functional materials.
Dosage Form : Tablet
Grade : Oral
SPI Pharma has been solving formulation challenges using superior functional materials.
Dosage Form : Tablet
Grade : Oral
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Gangwal Healthcare
Gangwal Healthcare is powered by innovation, driving health, wellness & healing.
Dosage Form : Tablet
Grade : Oral
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Pfanstiehl
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Gangwal Chemicals
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Ingredion Pharma Solutions
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Kerry
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Microlex e.U
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Pluviaendo
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Roquette
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Shanghai Shenmei Pharmaceutical Technology Co., Ltd
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Shijiazhuang Huaxu Pharmaceutical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Fillers, Diluents & Binders
Chewable & Orodispersible Aids
Taste Masking
Direct Compression
Disintegrants & Superdisintegrants
Parenteral
Co-Processed Excipients
Granulation
Solubilizers
Thickeners and Stabilizers
Digital Content
DATA COMPILATION #PharmaFlow
NEWS #PharmaBuzz
Global Sales Information
US Medicaid Prescriptions
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Market Place
APIs
Reply
27 Jan 2026
Reply
24 Sep 2025
Reply
17 May 2025
Reply
25 Apr 2025
Reply
27 Feb 2025
Reply
14 Feb 2025
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
REF. STANDARDS & IMPURITIES
EDQM
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]JP
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Others
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]ABOUT THIS PAGE
47
PharmaCompass offers a list of Carboplatin API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Carboplatin manufacturer or Carboplatin supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Carboplatin manufacturer or Carboplatin supplier.
PharmaCompass also assists you with knowing the Carboplatin API Price utilized in the formulation of products. Carboplatin API Price is not always fixed or binding as the Carboplatin Price is obtained through a variety of data sources. The Carboplatin Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Carboplatin manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Carboplatin, including repackagers and relabelers. The FDA regulates Carboplatin manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Carboplatin API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Carboplatin manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Carboplatin supplier is an individual or a company that provides Carboplatin active pharmaceutical ingredient (API) or Carboplatin finished formulations upon request. The Carboplatin suppliers may include Carboplatin API manufacturers, exporters, distributors and traders.
click here to find a list of Carboplatin suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Carboplatin DMF (Drug Master File) is a document detailing the whole manufacturing process of Carboplatin active pharmaceutical ingredient (API) in detail. Different forms of Carboplatin DMFs exist exist since differing nations have different regulations, such as Carboplatin USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Carboplatin DMF submitted to regulatory agencies in the US is known as a USDMF. Carboplatin USDMF includes data on Carboplatin's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Carboplatin USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Carboplatin suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Carboplatin Drug Master File in Japan (Carboplatin JDMF) empowers Carboplatin API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Carboplatin JDMF during the approval evaluation for pharmaceutical products. At the time of Carboplatin JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Carboplatin suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Carboplatin Drug Master File in Korea (Carboplatin KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Carboplatin. The MFDS reviews the Carboplatin KDMF as part of the drug registration process and uses the information provided in the Carboplatin KDMF to evaluate the safety and efficacy of the drug.
After submitting a Carboplatin KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Carboplatin API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Carboplatin suppliers with KDMF on PharmaCompass.
A Carboplatin CEP of the European Pharmacopoeia monograph is often referred to as a Carboplatin Certificate of Suitability (COS). The purpose of a Carboplatin CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Carboplatin EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Carboplatin to their clients by showing that a Carboplatin CEP has been issued for it. The manufacturer submits a Carboplatin CEP (COS) as part of the market authorization procedure, and it takes on the role of a Carboplatin CEP holder for the record. Additionally, the data presented in the Carboplatin CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Carboplatin DMF.
A Carboplatin CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Carboplatin CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Carboplatin suppliers with CEP (COS) on PharmaCompass.
A Carboplatin written confirmation (Carboplatin WC) is an official document issued by a regulatory agency to a Carboplatin manufacturer, verifying that the manufacturing facility of a Carboplatin active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Carboplatin APIs or Carboplatin finished pharmaceutical products to another nation, regulatory agencies frequently require a Carboplatin WC (written confirmation) as part of the regulatory process.
click here to find a list of Carboplatin suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Carboplatin as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Carboplatin API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Carboplatin as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Carboplatin and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Carboplatin NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Carboplatin suppliers with NDC on PharmaCompass.
Carboplatin Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Carboplatin GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Carboplatin GMP manufacturer or Carboplatin GMP API supplier for your needs.
A Carboplatin CoA (Certificate of Analysis) is a formal document that attests to Carboplatin's compliance with Carboplatin specifications and serves as a tool for batch-level quality control.
Carboplatin CoA mostly includes findings from lab analyses of a specific batch. For each Carboplatin CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Carboplatin may be tested according to a variety of international standards, such as European Pharmacopoeia (Carboplatin EP), Carboplatin JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Carboplatin USP).
Comment (1)
